DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Sweden
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
BICO logo

BICO Group AB (publ) Stock Price

OM:BICO Community·SEK 1.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 21 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

BICO Share Price Performance

SEK 0
-23.42 (-100.00%)
​
SEK 29.00
Fair Value
SEK 0
-23.42 (-100.00%)
​
Price SEK 0
Wed, 26 Aug 26
Fair ValueSEK 29.00
Share Pricen/a

BICO Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value SEK 29 29.5% undervalued intrinsic discount

Lab Automation And AI Software Adoption Will Drive Long-Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value SEK 23 11.1% undervalued intrinsic discount

Lab Automation Risks May Dominate Near Term Yet Long Term Prospects Appear Promising

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value SEK 39 47.6% undervalued intrinsic discount

Lab Automation And Connected Labs Will Reshape Long Term Potential For This Undervalued Business

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
BICO logo
BICO Group
47.6% undervalued intrinsic discount
Updated

Lab Automation And Connected Labs Will Reshape Long Term Potential For This Undervalued Business

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 9 Sep
Read Narrative
BICO logo
BICO Group
29.5% undervalued intrinsic discount

Lab Automation And AI Software Adoption Will Drive Long-Term Upside Potential

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 26 Aug
Read Narrative
BICO logo
BICO Group
11.1% undervalued intrinsic discount

Lab Automation Risks May Dominate Near Term Yet Long Term Prospects Appear Promising

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 26 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
BICO logo

BICO: Leadership Transition And Margin Focus Will Support Future Upside

Fair Value: SEK 39 47.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
BICO logo

BICO: Leadership Transition And Revised Assumptions Will Support Future Repricing

Fair Value: SEK 29 29.5% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
BICO logo

BICO: Long Term Incentive Plan Will Support Future Shareholder Return

Fair Value: SEK 23 11.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet.

1 Risk
3 Rewards
View Full Analysis

BICO Group AB (publ) Key Details

SEK 1.5b

Revenue

SEK 678.4m

Cost of Revenue

SEK 825.8m

Gross Profit

SEK 2.2b

Other Expenses

-SEK 1.3b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 11, 2026
-18.90
54.90%
-88.69%
26.9%
View Full Analysis

About BICO

Founded
2016
Employees
554
CEO
Anders Fogelberg
WebsiteView website
bico.com

BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.

Recent BICO News & Updates

User avatar
Narrative Update • Sep 09

BICO: Leadership Transition And Margin Focus Will Support Future Upside

Analysts have lifted their price target on BICO Group to SEK39 from SEK31 as they incorporate a lower discount rate, slightly revised revenue and margin forecasts, and a higher assumed future P/E multiple in their updated valuation work. What’s in the News for BICO Group BICO Group plans a CEO transition with Anders Fogelberg appointed as CEO, effective 1 September 2026.
User avatar
Narrative Update • Aug 26

BICO: Leadership Transition And Revised Assumptions Will Support Future Repricing

Analysts have raised their SEK price target for BICO Group from SEK 23.50 to SEK 29.00, citing updated assumptions that include a different discount rate, revenue growth outlook, profit margin profile, and future P/E multiple. What’s in the News for BICO Group BICO Group appointed Anders Fogelberg, currently Chief Commercial Officer, as CEO effective September 1, 2026, according to a company announcement.

Recent updates

No updates

BICO Group AB (publ) Competitors

CAMX logo

Camurus

Symbol: OM:CAMX
Market cap: SEK 34.8b
BIOA B logo

BioArctic

Symbol: OM:BIOA B
Market cap: SEK 28.4b
ALIF B logo

AddLife

Symbol: OM:ALIF B
Market cap: SEK 19.3b
BONEX logo

Bonesupport Holding

Symbol: OM:BONEX
Market cap: SEK 14.3b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide